These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27749585)

  • 1. A case report of the beneficial effects of botulinum toxin type A on Raynaud phenomenon in a patient with lung cancer.
    Wang L; Lei QS; Liu YY; Song GJ; Song CL
    Medicine (Baltimore); 2016 Oct; 95(40):e5092. PubMed ID: 27749585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon.
    Fregene A; Ditmars D; Siddiqui A
    J Hand Surg Am; 2009 Mar; 34(3):446-52. PubMed ID: 19258141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Use of Botulinum Toxin in Raynaud Phenomenon: A Comprehensive Literature Review.
    Lawson O; Sisti A; Konofaos P
    Ann Plast Surg; 2023 Jul; 91(1):159-186. PubMed ID: 37450876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum Toxin for the Treatment of Intractable Raynaud Phenomenon.
    Gallegos JE; Inglesby DC; Young ZT; Herrera FA
    J Hand Surg Am; 2021 Jan; 46(1):54-59. PubMed ID: 32948347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Raynaud's phenomenon with botulinum toxin type A.
    Zhang X; Hu Y; Nie Z; Song Y; Pan Y; Liu Y; Jin L
    Neurol Sci; 2015 Jul; 36(7):1225-31. PubMed ID: 25616446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin type A in the treatment of Raynaud's phenomenon.
    Habib SM; Brenninkmeijer EEA; Vermeer MH; de Vries-Bouwstra JK; Velthuis PJ
    Dermatol Ther; 2020 Nov; 33(6):e14182. PubMed ID: 32794364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of botulinum toxin in vasospastic disorders of the hand.
    Neumeister MW
    Hand Clin; 2015 Feb; 31(1):23-37. PubMed ID: 25455354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum Toxin A Treatment for Primary and Secondary Raynaud's Phenomenon in Teenagers.
    Quintana Castanedo L; Feito Rodríguez M; Nieto Rodríguez D; Maseda Pedrero R; Chiloeches Fernández C; de Lucas Laguna R
    Dermatol Surg; 2021 Jan; 47(1):61-64. PubMed ID: 32371783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Bello RJ; Cooney CM; Melamed E; Follmar K; Yenokyan G; Leatherman G; Shah AA; Wigley FM; Hummers LK; Lifchez SD
    Arthritis Rheumatol; 2017 Aug; 69(8):1661-1669. PubMed ID: 28426903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study.
    Motegi S; Yamada K; Toki S; Uchiyama A; Kubota Y; Nakamura T; Ishikawa O
    J Dermatol; 2016 Jan; 43(1):56-62. PubMed ID: 26173902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimally invasive treatment of Raynaud phenomenon: the role of botulinum type A.
    Neumeister MW; Webb KN; Romanelli M
    Hand Clin; 2014 Feb; 30(1):17-24. PubMed ID: 24286738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin-A for the treatment of Raynaud syndrome.
    Smith L; Polsky D; Franks AG
    Arch Dermatol; 2012 Apr; 148(4):426-8. PubMed ID: 22508867
    [No Abstract]   [Full Text] [Related]  

  • 14. Optimisation of botulinum toxin type a treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case series.
    Dhaliwal K; Griffin MF; Salinas S; Howell K; Denton CP; Butler PEM
    Clin Rheumatol; 2019 Dec; 38(12):3669-3676. PubMed ID: 31482318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin type A in the treatment of Raynaud's phenomenon.
    Neumeister MW
    J Hand Surg Am; 2010 Dec; 35(12):2085-92. PubMed ID: 21134617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin A treatment of Raynaud's phenomenon: a review.
    Iorio ML; Masden DL; Higgins JP
    Semin Arthritis Rheum; 2012 Feb; 41(4):599-603. PubMed ID: 21868066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum Toxins for the Treatment of Raynaud Phenomenon: A Systematic Review With Meta-analysis.
    Zhou Y; Yu Y; Bi S; Cen Y
    J Clin Rheumatol; 2023 Aug; 29(5):e92-e99. PubMed ID: 37011178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted high concentration botulinum toxin A injections in patients with Raynaud's phenomenon: a retrospective single-centre experience.
    Nagarajan M; McArthur P
    Rheumatol Int; 2021 May; 41(5):943-949. PubMed ID: 32447423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum Toxin in the Long-Term Treatment of Refractory Raynaud’s Phenomenon.
    Asad U; Austin B; Tarbox M; Paulger B
    J Drugs Dermatol; 2019 Sep; 18(9):943-945. PubMed ID: 31524993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and image improvement of Raynaud's phenomenon after botulinum toxin type A treatment.
    Zhao H; Lian Y
    Australas J Dermatol; 2015 Aug; 56(3):202-5. PubMed ID: 25817568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.